![]() ![]() The FDA approved the on-label Recover IV randomized controlled trial involving acute myocardial infarction (AMI) cardiogenic shock patients. The FDA approved clinical research into using Impella heart pumps in severe heart attack patients with cardiogenic shock in September. > FDA approves new research around Abiomed Impella heart pumpsĪbiomed’s heart pumps excelled in the second half of the 2022 calendar year. It is less invasive than some left ventricle assist devices (LVADs) and can allow patients with chronic heart failure to have a longer-term minimally invasive heart pump option. The company designed the implant to pump more than six liters of blood per minute. Impella BTR is forward-flow heart pump implanted through the axillary artery and placed in the left ventricle. In April 2022, Abiomed announced the first implants of its Impella Bridge-to-Recovery (BTR) as part of an early feasibility study. > First implants of Impella Bridge-to-Recovery (BTR) Here are some of Abiomed’s research-driven news in 2022: But the company produced a lot of innovation news and research results throughout 2022. Abiomed’s Impella RP with Smart Assist The biggest news from Danvers, Massachusetts-based Abiomed came in November when it announced that medtech giant Johnson & Johnson would acquire it for more than $16 billion.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |